ProteoGenix Launches New Transient Expression System

Published on: 
BP Elements, BioPharm International's BP Elements, April 2022, Volume 1, Issue 4

ProteoGenix’s new XtenCHO Transient Expression can achieve up to ten times higher yields than market-leading CHO systems.

ProteoGenix, a France-based biotech contract research organization, announced the launch of XtenCHO Transient Expression System on March 15, 2022. This new expression system can achieve up to ten times higher yields with less hands-on time when compared to existing solutions because of enhanced plasmid stability and optimized metabolism, according to a company press release.

ProteoGenix developed XtenCHO from the parental cell line Chinese hamster ovary (CHO)-K1 by engineering its genome to exhibit properties that maximize protein production yields. An animal component-free growth medium, highly efficient transfection reagent, and ultra-high expression vector work together to reduce premature plasmid loss, creating a three to ten-fold increase in transient gene expression yields compared to market-leading CHO systems. The company also states that the product has an enhanced robustness that allows it to recover quickly after thawing and perform satisfactorily in suboptimal conditions.

“The new XtenCHO system produces monoclonal antibodies that are indistinguishable from biopharmaceutical-grade biologics produced in stable systems,” said Raphaël Hopfner, chief scientific officer and co-founder, ProteoGenix, in the press release. “This eases process scalability and reduces the risks when transitioning from the bench to the clinic.”

“We have launched XtenCHO to help speed up the process of early drug development; making it safer, more flexible, accessible and easier to integrate into existing biologics discovery workflows using cost-effective reagents to achieve very high yields,” said Philippe Funfrock, CEO and co-founder, ProteoGenix, in the press release.


ProteoGenix’s new host has been used and optimized by ProteoGenix for approximately five years, creating more than 3500 recombinant proteins. This includes antibodies from multiple species, isotopes, and formats, including bispecific antibodies, antibody drug conjugates, and nanobodies. Non-antibody proteins, such as highly functional enzymes, membrane-bound receptors, cytokines, interleukins, and transcription factors, have also been produced.

Source: ProteoGenix